Drug Profile
Ravulizumab - Alexion AstraZeneca Rare Disease
Alternative Names: ALXN 1210; ALXN 1810; ravulizumab-cwvz; UltomirisLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Alexion Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease; AstraZeneca
- Class Anti-inflammatories; Antithrombotics; Eye disorder therapies; Monoclonal antibodies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemolytic uraemic syndrome; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
- Registered Neuromyelitis optica
- Phase III Acute kidney injury; Thrombotic microangiopathies
- Phase II IgA nephropathy; Lupus nephritis
- Discontinued Acute lung injury; Amyotrophic lateral sclerosis; COVID-19 pneumonia; Dermatomyositis; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 25 Mar 2024 Registered for Neuromyelitis optica in USA (IV)
- 04 Mar 2024 Alexion Pharmaceuticals plans a phase III trial for IgA nephropathy (Treatment-experienced) in the US, Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Greece, Italy, Japan, South Korea, Mexico, Netherlands, Poland, Saudi Arabia, Spain, Taiwan, Thailand, Turkey (IV, Infusion), in April 2024 (NCT06291376)
- 29 Feb 2024 Efficacy and adverse events data from a phase III clinical trials in Neuromyelitis optica presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)